SEARCH

SEARCH BY CITATION

References

  • Adkins E. M., Samuvel D. J., Fog J. U., Eriksen J., Jayanthi L. D., Vaegter C. B., Ramamoorthy S. and Gether U. (2007) Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 46, 1048410497.
  • Albin R. L. and Mink J. W. (2006) Recent advances in Tourette syndrome research. Trends Neurosci. 29, 175182.
  • Baron A., Deval E., Salinas M., Lingueglia E., Voilley N. and Lazdunski M. (2002) Protein kinase C stimulates the acid-sensing ion channel ASIC2a via the PDZ domain-containing protein PICK1. J. Biol. Chem. 277, 5046350468.
  • Bauman A. L., Apparsundaram S., Ramamoorthy S., Wadzinski B. E., Vaughan R. A. and Blakely R. D. (2000) Cocaine and antidepressant-sensitive biogenic amine transporters exist in regulated complexes with protein phosphatase 2A. J. Neurosci. 20, 75717578.
  • Beuming T., Shi L., Javitch J. A. and Weinstein H. (2006) A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol. Pharmacol. 70, 16301642.
  • Beuming T., Kniazeff J., Bergmann M. L. et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat. Neurosci. 11, 780789.
  • Binda F., Dipace C., Bowton E. et al. (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol. Pharmacol. 74, 11011108.
  • Bjerggaard C., Fog J. U., Hastrup H., Madsen K., Loland C. J., Javitch J. A. and Gether U. (2004) Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J. Neurosci. 24, 70247036.
  • Bjorklund A. and Dunnett S. B. (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci. 30, 194202.
  • Bolan E. A., Kivell B., Jaligam V. et al. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71, 12221232.
  • Boudanova E., Navaroli D. M., Stevens Z. and Melikian H. E. (2008) Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. Mol. Cell. Neurosci. 39, 211217.
  • Browman K. E., Kantor L., Richardson S., Badiani A., Robinson T. E. and Gnegy M. E. (1998) Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Brain Res. 814, 112119.
  • Carlsson A., Lindqvist M. and Magnusson T. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200.
  • Carlsson A., Lindqvist M., Magnusson T. and Waldeck B. (1958) On the presence of 3-hydroxytyramine in brain. Science 127, 471.
  • Carneiro A. M. and Blakely R. D. (2006) Serotonin-, protein kinase C-, and Hic-5-associated redistribution of the platelet serotonin transporter. J. Biol. Chem. 281, 2476924780.
  • Carneiro A. M., Ingram S. L., Beaulieu J. M., Sweeney A., Amara S. G., Thomas S. M., Caron M. G. and Torres G. E. (2002) The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J. Neurosci. 22, 70457054.
  • Carvelli L., Moron J. A., Kahlig K. M. et al. (2002) PI 3-kinase regulation of dopamine uptake. J. Neurochem. 81, 859869.
  • Carvelli L., McDonald P. W., Blakely R. D. and DeFelice L. J. (2004) Dopamine transporters depolarize neurons by a channel mechanism. Proc. Natl Acad. Sci. USA 101, 1604616051.
  • Carvelli L., Blakely R. D. and DeFelice L. J. (2008) Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proc. Natl Acad. Sci. USA 105, 1419214197.
  • Cervinski M. A., Foster J. D. and Vaughan R. A. (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J. Biol. Chem. 280, 4044240449.
  • Cha J. H., Zou M. F., Adkins E. M., Rasmussen S. G., Loland C. J., Schoenenberger B., Gether U. and Newman A. H. (2005) Rhodamine-labeled 2beta-carbomethoxy-3beta-(3,4-dichlorophenyl)tropane analogues as high-affinity fluorescent probes for the dopamine transporter. J. Med. Chem. 48, 75137516.
  • Chandra S., Fornai F., Kwon H. B. et al. (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc. Natl Acad. Sci. USA 101, 1496614971.
  • Chen N. H., Reith M. and Quick M. (2004) Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. Eur. J. Physiol. 447, 519531.
  • Chen R., Tilley M. R., Wei H. et al. (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. PNAS 103, 93339338.
  • Chen R., Furman C. A., Zhang M., Kim M. N., Gereau R. W., IV, Leitges M. and Gnegy M. E. (2009) Protein kinase C{beta} is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J. Pharmacol. Exp. Ther. 328, 912920.
  • Chi L. and Reith M. E. A. (2003) Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J. Pharmacol. Exp. Ther. 307, 729736.
  • Ciccone M. A., Timmons M., Phillips A. and Quick M. W. (2008) Calcium/calmodulin-dependent kinase II regulates the interaction between the serotonin transporter and syntaxin 1A. Neuropharmacology 55, 763770.
  • Copeland B. J., Vogelsberg V., Neff N. H. and Hadjiconstantinou M. (1996) Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 277, 15271532.
  • Cowell R. M., Kantor L., Hewlett G. H. K., Frey K. A. and Gnegy M. E. (2000) Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389, 5965.
  • Daniels G. M. and Amara S. G. (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274, 3579435801.
  • Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 1452414529.
  • Daws L. C., Callaghan P. D., Moron J. A., Kahlig K. M., Shippenberg T. S., Javitch J. A. and Galli A. (2002) Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290, 15451550.
  • Deken S. L., Beckman M. L., Boos L. and Quick M. W. (2000) Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A. Nat. Neurosci. 3, 9981003.
  • Dipace C., Sung U., Binda F., Blakely R. D. and Galli A. (2007) Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Mol. Pharmacol. 71, 230239.
  • Egana L. A., Cuevas R. A., Baust T. B. et al. (2009) Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J. Neurosci. 29, 45924604.
  • Eriksen J., Rasmussen S. G. F., Rasmussen T. N., Vaegter C. B., Cha J. H., Zou M. F., Newman A. H. and Gether U. (2009) Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J. Neurosci. 29, 67946808.
  • Farhan H., Korkhov V. M., Paulitschke V., Dorostkar M. M., Scholze P., Kudlacek O., Freissmuth M. and Sitte H. H. (2004) Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1). J. Biol. Chem. 279, 2855328563.
  • Farhan H., Freissmuth M. and Sitte H. H. (2006) Oligomerization of neurotransmitter transporters: a ticket from the endoplasmic reticulum to the plasma membrane. Handb. Exp. Pharmacol. 175, 233249.
  • Farhan H., Reiterer V., Korkhov V. M., Schmid J. A., Freissmuth M. and Sitte H. H. (2007) Concentrative export from the endoplasmic reticulum of the gamma-aminobutyric acid transporter 1 requires binding to SEC24D. J. Biol. Chem. 282, 76797689.
  • Fog J. U., Khoshbouei H., Holy M. et al. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51, 417429.
  • Foster J. D., Pananusorn B. and Vaughan R. A. (2002) Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J. Biol. Chem. 277, 2517825186.
  • Foster J. D., Adkins S. D., Lever J. R. and Vaughan R. A. (2008) Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J. Neurochem. 105, 16831699.
  • Fountaine T. M. and Wade-Martins R. (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 85, 351363.
  • Fountaine T. M., Venda L. L., Warrick N., Christian H. C., Brundin P., Channon K. M. and Wade-Martins R. (2008) The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons. Eur. J. Neurosci. 28, 24592473.
  • Fumagalli F., Gainetdinov R. R., Valenzano K. J. and Caron M. G. (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18, 48614869.
  • Garcia B. G., Wei Y., Moron J. A., Lin R. Z., Javitch J. A. and Galli A. (2005) Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol. Pharmacol. 68, 102109.
  • Gether U. (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90113.
  • Gether U., Andersen P. H., Larsson O. M. and Schousboe A. (2006) Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 27, 375383.
  • Giros B., Jaber M., Jones S. R., Wightman R. M. and Caron M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606612.
  • Gorentla B. K., Moritz A. E., Foster J. D. and Vaughan R. A. (2009) Proline-directed phosphorylation of the dopamine transporter N-terminal domain. Biochemistry 48, 10671076.
  • Granas C., Ferrer J., Loland C. J., Javitch J. A. and Gether U. (2003) N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J. Biol. Chem. 278, 49905000.
  • Greene J. G. (2006) Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J. Physiol. 575, 411416.
  • Groc L. and Choquet D. (2008) Measurement and characteristics of neurotransmitter receptor surface trafficking (Review). Mol. Membr. Biol. 25, 344352.
  • Gu H., Wall S. C. and Rudnick G. (1994) Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269, 71247130.
  • Gubernator N. G., Zhang H., Staal R. G. W. et al. (2009) Fluorescent false neurotransmitters visualize dopamine release from individual presynaptic terminals. Science 324, 14411444.
  • Hanley J. G. and Henley J. M. (2005) PICK1 is a calcium-sensor for NMDA-induced AMPA receptor trafficking. EMBO J. 24, 32663278.
  • Hastrup H., Karlin A. and Javitch J. A. (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc. Natl Acad. Sci. USA 98, 1005510060.
  • Hersch S. M., Yi H., Heilman C. J., Edwards R. H. and Levey A. I. (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. Comp. Neurol. 388, 211227.
  • Holton K. L., Loder M. K. and Melikian H. E. (2005) Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8, 881888.
  • Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y. and Takahashi R. (2001) An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891902.
  • Ingram S. L., Prasad B. M. and Amara S. G. (2002) Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat. Neurosci. 5, 971978.
  • Iversen S. D. and Iversen L. L. (2007) Dopamine: 50 years in perspective. Trends Neurosci. 30, 188193.
  • Jayanthi L. D., Samuvel D. J., Blakely R. D. and Ramamoorthy S. (2005) Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol. Pharmacol. 67, 20772087.
  • Jeannotte A. M. and Sidhu A. (2007) Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules. Eur. J. Neurosci. 26, 15091520.
  • Johnson L. A., Guptaroy B., Lund D., Shamban S. and Gnegy M. E. (2005) Regulation of amphetamine-stimulated dopamine efflux by protein kinase C {beta}. J. Biol. Chem. 280, 1091410919.
  • Jones S. R., Gainetdinov R. R., Jaber M., Giros B., Wightman R. M. and Caron M. G. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl Acad. Sci. USA 95, 40294034.
  • Jorgensen S., Nielsen E. Ï., Peters D. and Dyhring T. (2008) Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity. J. Neurosci. Methods 169, 168176.
  • Kahlig K. M., Binda F., Khoshbouei H., Blakely R. D., McMahon D. G., Javitch J. A. and Galli A. (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl Acad. Sci. USA 102, 34953500.
  • Kantor L. and Gnegy M. E. (1998) Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J. Pharmacol. Exp. Ther. 284, 592598.
  • Khoshbouei H., Sen N., Guptaroy B., Johnson L., Lund D., Gnegy M. E., Galli A. and Javitch J. A. (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2, E78.
  • Kim E. and Sheng M. (2004) PDZ domain proteins of synapses. Nat. Rev. Neurosci. 5, 771781.
  • Kniazeff J., Shi L., Loland C. J., Javitch J. A., Weinstein H. and Gether U. (2008) An intracellular interaction network regulates conformational transitions in the dopamine transporter. J. Biol. Chem. 283, 1769117701.
  • Krueger B. K. (1990) Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55, 260267.
  • Kruger R., Kuhn W., Muller T. et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106108.
  • Lammel S., Hetzel A., HΣckel O., Jones I., Liss B. and Roeper J. (2008) Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57, 760773.
  • Lee F. J., Liu F., Pristupa Z. B. and Niznik H. B. (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916926.
  • Lee K. H., Kim M. Y., Kim D. H. and Lee Y. S. (2004) Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem. Res. 29, 14051409.
  • Lee F. J., Pei L., Moszczynska A., Vukusic B., Fletcher P. J. and Liu F. (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 26, 21272136.
  • Lee F. J., Pei L. and Liu F. (2009) Disruption of the dopamine transporter-dopamine D2 receptor interaction in schizophrenia. Synapse 63, 710712.
  • LeWitt P. A. (2008) Levodopa for the treatment of Parkinson’s disease. N. Engl. J. Med. 359, 24682476.
  • Lin D. T. and Huganir R. L. (2007) PICK1 and phosphorylation of the glutamate receptor 2 (GluR2) AMPA receptor subunit regulates GluR2 recycling after NMDA receptor-induced internalization. J. Neurosci. 27, 1390313908.
  • Maiya R., Ponomarev I., Linse K. D., Harris R. A. and Mayfield R. D. (2007) Defining the dopamine transporter proteome by convergent biochemical and in silico analyses. Genes Brain Behav. 6, 97106.
  • Marazziti D., Golini E., Mandillo S., Magrelli A., Witke W., Matteoni R. and Tocchini-Valentini G. P. (2004) Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson’s disease-associated GPR37/parkin-associated endothelin-like receptor. PNAS 101, 1018910194.
  • Marazziti D., Mandillo S., Di Pietro C., Golini E., Matteoni R. and Tocchini-Valentini G. P. (2007) GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. PNAS 104, 98469851.
  • Mazei-Robison M. S. and Blakely R. D. (2005) Expression studies of naturally occurring human dopamine transporter variants identifies a novel state of transporter inactivation associated with Val382Ala. Neuropharmacology 49, 737749.
  • McDonald P. W., Hardie S. L., Jessen T. N., Carvelli L., Matthies D. S. and Blakely R. D. (2007) Vigorous motor activity in Caenorhabditis elegans requires efficient clearance of dopamine mediated by synaptic localization of the dopamine transporter DAT-1. J. Neurosci. 27, 1421614227.
  • Mehrens T., Lelleck S., Cetinkaya I., Knollmann M., Hohage H., Gorboulev V., Boknik P., Koepsell H. and Schlatter E. (2000) The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J. Am. Soc. Nephrol. 11, 12161224.
  • Meinild A. K., Sitte H. H. and Gether U. (2004) Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter. J. Biol. Chem. 279, 4967149679.
  • Melikian H. E. and Buckley K. M. (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19, 76997710.
  • Miranda M., Wu C. C., Sorkina T., Korstjens D. R. and Sorkin A. (2005) Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C. J. Biol. Chem. 280, 3561735624.
  • Miranda M., Dionne K. R., Sorkina T. and Sorkin A. (2007) Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol. Biol. Cell 18, 313323.
  • Montagu K. A. (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180, 244245.
  • Moron J. A., Zakharova I., Ferrer J. V. et al. (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23, 84808488.
  • Moszczynska A., Saleh J., Zhang H., Vukusic B., Lee F. J. and Liu F. (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J. Mol. Neurosci. 32, 217227.
  • Nestler E. J. (2005) The neurobiology of cocaine addiction. Sci. Pract. Perspect. 3, 410.
  • Nourry C., Grant S. G. N. and Borg J. P. (2003) PDZ domain proteins: plug and play! Sci. STKE 2003, re7.
  • Ohyama A., Hosaka K., Komiya Y. et al. (2002) Regulation of exocytosis through Ca2+/ATP-dependent binding of autophosphorylated Ca2+/calmodulin-activated protein kinase II to syntaxin 1A. J. Neurosci. 22, 33423351.
  • Perez J. L., Khatri L., Chang C., Srivastava S., Osten P. and Ziff E. B. (2001) PICK1 targets activated protein kinase C{alpha} to AMPA receptor clusters in spines of hippocampal neurons and reduces surface levels of the AMPA-type glutamate receptor subunit 2. J. Neurosci. 21, 54175428.
  • Pifl C. and Singer E. A. (1999) Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol. Pharmacol. 56, 10471054.
  • Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276, 20452047.
  • Quick M. W. (2003) Regulating the conducting states of a mammalian serotonin transporter. Neuron 40, 537549.
  • Raiborg C. and Stenmark H. (2009) The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445452.
  • Rayport S., Sulzer D., Shi W. X., Sawasdikosol S., Monaco J., Batson D. and Rajendran G. (1992) Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J. Neurosci. 12, 42644280.
  • Saunders C., Ferrer J. V., Shi L. et al. (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl Acad. Sci. USA 97, 68506855.
  • Schapira A. H. V. (2009) Neurobiology and treatment of Parkinson’s disease. Trends Pharmacol. Sci. 30, 4147.
  • Scholze P., Freissmuth M. and Sitte H. H. (2002a) Mutations within an intramembrane leucine heptad repeat disrupt oligomer formation of the rat GABA transporter 1. J. Biol. Chem. 277, 4368243690.
  • Scholze P., Norregaard L., Singer E. A., Freissmuth M., Gether U. and Sitte H. H. (2002b) The role of zinc ions in reverse transport mediated by monoamine transporters. J. Biol. Chem. 277, 2150521513.
  • Schwartz J. W., Blakely R. D. and DeFelice L. J. (2003) Binding and transport in norepinephrine transporters. Real-time, spatially resolved analysis in single cells using a fluorescent substrate. J. Biol. Chem. 278, 97689777.
  • Schwartz J. W., Novarino G., Piston D. W. and DeFelice L. J. (2005) Substrate binding stoichiometry and kinetics of the norepinephrine transporter. J. Biol. Chem. 280, 1917719184.
  • Silva N. L., Mariani A. P., Harrison N. L. and Barker J. L. (1988) 5,7-Dihydroxytryptamine identifies living dopaminergic neurons in mesencephalic cultures. Proc. Natl Acad. Sci. USA 85, 73467350.
  • Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302, 841.
  • Sitte H. H., Huck S., Reither H., Boehm S., Singer E. A. and Pifl C. (1998) Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem. 71, 12891297.
  • Sitte H. H., Farhan H. and Javitch J. A. (2004) Sodium-dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol. Interv. 4, 3847.
  • Sonders M. S., Zhu S. J., Zahniser N. R., Kavanaugh M. P. and Amara S. G. (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17, 960974.
  • Sorkina T., Doolen S., Galperin E., Zahniser N. R. and Sorkin A. (2003) Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278, 2827428283.
  • Sorkina T., Hoover B. R., Zahniser N. R. and Sorkin A. (2005) Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6, 157170.
  • Sorkina T., Miranda M., Dionne K. R., Hoover B. R., Zahniser N. R. and Sorkin A. (2006) RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis. J. Neurosci. 26, 81958205.
  • Sorkina T., Richards T. L., Rao A., Zahniser N. R. and Sorkin A. (2009) Negative regulation of dopamine transporter endocytosis by membrane-proximal N-terminal residues. J. Neurosci. 29, 13611374.
  • Sulzer D., Sonders M. S., Poulsen N. W. and Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406433.
  • Sung U., Apparsundaram S., Galli A., Kahlig K. M., Savchenko V., Schroeter S., Quick M. W. and Blakely R. D. (2003) A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J. Neurosci. 23, 16971709.
  • Thomsen M., Han D. D., Gu H. H. and Caine S. B. (2009) Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. J. Pharmacol. Exp. Ther. 331, 204211.
  • Tomlinson I. D., Mason J. N., Blakely R. D. and Rosenthal S. J. (2005) Inhibitors of the serotonin transporter protein (SERT): the design and synthesis of biotinylated derivatives of 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indoles. High-affinity serotonergic ligands for conjugation with quantum dots. Bioorg. Med. Chem. Lett. 15, 53075310.
  • Tomlinson I. D., Mason J. N., Blakely R. D. and Rosenthal S. J. (2006) High affinity inhibitors of the dopamine transporter (DAT): novel biotinylated ligands for conjugation to quantum dots. Bioorg. Med. Chem. Lett. 16, 46644667.
  • Torres G. E. and Amara S. G. (2007) Glutamate and monoamine transporters: new visions of form and function. Curr. Opin. Neurobiol. 17, 304312.
  • Torres G. E., Yao W. D., Mohn A. R., Quan H., Kim K. M., Levey A. I., Staudinger J. and Caron M. G. (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30, 121134.
  • Torres G. E., Carneiro A., Seamans K., Fiorentini C., Sweeney A., Yao W. D. and Caron M. G. (2003) Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J. Biol. Chem. 278, 27312739.
  • Vaughan R. A., Huff R. A., Uhl G. R. and Kuhar M. J. (1997) Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272, 1554115546.
  • Wall S. C., Gu H. and Rudnick G. (1995) Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47, 544550.
  • Wersinger C. and Sidhu A. (2003) Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with alpha-synuclein and its familial Parkinson’s disease-linked mutants. Neurosci. Lett. 342, 124128.
  • Williams J. M., Owens W. A., Turner G. H. et al. (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol. 5, e274.
  • Yamashita A., Singh S. K., Kawate T., Jin Y. and Gouaux E. (2005) Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature 437, 215223.
  • Zapata A., Kivell B., Han Y. et al. (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J. Biol. Chem. 282, 3584235854.
  • Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164173.
  • Zhu S. J., Kavanaugh M. P., Sonders M. S., Amara S. G. and Zahniser N. R. (1997) Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 282, 13581365.